{"id":"W2905465042","doi":"10.1182/blood-2018-99-114656","title":"Second Attempt of TKI Discontinuation with Dasatinib for Treatment-Free Remission after Failing First Attempt with Imatinib: Treatment-Free Remission Accomplished By Dasatinib (TRAD) Trial","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"ca_institutions":"Hamilton Health Sciences; McGill University Health Centre; Alberta Hospital Edmonton; London Health Sciences Centre; Juravinski Cancer Centre; Hôpital de l'Enfant-Jésus; Princess Margaret Cancer Centre; University of Calgary; Université de Montréal; Leukemia & Lymphoma Society of Canada; Université Laval; Queen Elizabeth II Health Sciences Centre; Hôpital Maisonneuve-Rosemont; Health Sciences Centre; CancerCare Manitoba; University of Alberta Hospital; Ottawa Hospital; University Health Network","funders":"","keywords":"Discontinuation; Medicine; Dasatinib; Internal medicine; Imatinib; Imatinib mesylate; Oncology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002507731,0.0006318128,0.001516093,0.0001613137,0.0002700535,0.0008565628,0.0005961487,0.000824131,0.003962696],"category_scores_gemma":[0.001232097,0.0001432138,0.001507614,0.0002259282,0.0003800608,0.0004545819,0.0002317052,0.001965256,0.0005965246],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007917786,"about_ca_system_score_gemma":0.001200663,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007063114,"about_ca_topic_score_gemma":0.001957786,"domain_scores_codex":[0.9991913,0.0003428996,0.00006045127,0.0001754513,0.00009752884,0.0001322631],"domain_scores_gemma":[0.9987992,0.0002957823,0.0002605986,0.0001753728,0.00007517992,0.0003938808],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8889776,0.008599015,0.008802195,0.0009918779,0.00246754,0.0002886568,0.0001666903,0.0008478331,0.008760966,0.000583865,0.003857835,0.07565587],"study_design_scores_gemma":[0.6767644,0.2847615,0.02292558,0.000110578,0.0015105,0.0006981409,0.00006007715,0.001122141,0.003600896,0.0003965658,0.008009544,0.00004012342],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9884825,0.004267081,0.0006021644,0.0005944491,0.0001966807,0.001187514,0.001310548,0.00005705086,0.003301978],"genre_scores_gemma":[0.9943724,0.0007660714,0.0004962484,0.0004440312,0.0001673015,0.0005746601,0.001431401,0.000009519286,0.001738341],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003962696,"threshold_uncertainty_score":0.01326233,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01882563202833285,"score_gpt":0.2718592563965646,"score_spread":0.2530336243682317,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}